4/25
08:30 am
aplm
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
Low
Report
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
4/10
07:00 am
aplm
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Low
Report
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
4/2
08:00 am
aplm
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Medium
Report
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
4/1
08:09 am
aplm
Apollomics, Inc. (NASDAQ: APLM) had its price target lowered by analysts at HC Wainwright from $17.00 to $5.00. They now have a "buy" rating on the stock.
High
Report
Apollomics, Inc. (NASDAQ: APLM) had its price target lowered by analysts at HC Wainwright from $17.00 to $5.00. They now have a "buy" rating on the stock.
3/28
07:00 am
aplm
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
High
Report
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
3/26
08:00 am
aplm
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
Medium
Report
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
3/4
07:00 am
aplm
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
Medium
Report
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
2/7
07:00 am
aplm
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Medium
Report
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference